Insulin resistance is a metabolic syndrome commonly seen in obesity. Leptin, the obese gene product, plays a role in the regulation of cardiac function. Elevated leptin levels have been demonstrated under insulin-resistant states such as obesity and hypertension, although their role in cardiac dysfunction is unknown. This study was designed to determine the impact of prediabetic insulin resistance on leptin levels and leptin-induced cardiac contractile response. Whole-body insulin resistance was generated with a 10-week dietary sucrose feeding. Contractile and intracellular Ca 2+ properties were evaluated in ventricular myocytes using an IonOptixt system. The contractile indices analyzed included peak shortening (PS), time-to-PS (TPS), time-to-90% relengthening (TR 90 ), maximal velocity of shortening/relengthening (7dL/dt), fura-fluorescence intensity change (DFFI) and decay rate (t). Sucrose-fed rats displayed significantly elevated body weight and plasma leptin levels, depressed PS, 7dL/dt, shortened TPS, prolonged TR 90 and t, as well as reduced DFFI compared to the starch-fed control group. Leptin (1-1000 nM) elicited a concentration-dependent depression of PS and DFFI in myocytes from both starch and sucrose groups. Leptin-induced contractile depression was abolished by the nitric oxide synthase inhibitor No-nitro-L-arginine methyle ester, elevation of the extracellular Ca 2+ concentration, the Janus activated kinase 2 inhibitor AG-490 or the mitogen activated protein kinase inhibitor SB203580 in myocytes from both sucrose and starch groups. Moreover, AG-490 and SB203580 unmasked a positive response of PS in myocytes from both groups. These data indicate that insulin resistance directly induces hyperleptinemia and cardiac contractile dysfunction, without affecting leptin-mediated cardiac contractile function at the myocyte level.
Introduction
Leptin, a 16 kDa obesity gene product, is produced by mature adipocytes. Its plasma levels are strongly correlated with adipose mass in both humans and rodents. Leptin inhibits food intake, reduces body weight and stimulates energy expenditure. It has been speculated that leptin plays a key role in obesity and diabetes since its expression increases after food intake and decreases during fasting and hyperglycemia. 1, 2 The physiological role of leptin in body function was further substantiated by the observations that insulin and glucocorticoids enhance leptin expression, whereas catecholamines and long-chain fatty acids depress its expression. 2 Recent evidence has demonstrated an essential role of leptin in the regulation of cardiovascular function either via direct myogenic route or through autonomic nervous control indirectly. 1, 3, 4 Several signaling pathways have been confirmed in the cardiovascular regulation of leptin including Janus activated kinase (JAK), signal transducer and activators of transcription (STAT), mitogen activated protein (MAP) kinase and nitric oxide (NO). 4, 5 However, little attempt has been made toward understanding the pathophysiological role of leptin in the onset of ventricular dysfunction under certain hyperleptinemic conditions such as obesity and hypertension. Obesity and hypertension are commonly associated with the development of insulin resistance and diabetes. 6 Clinical as well as experimental evidence has validated a strong association between the plasma leptin levels and insulinresistant states under obesity and hypertension. Leptin has been shown to paradoxically improve or to induce insulin resistance, suggesting a complex interplay or crosstalk between the direct peripheral and central effects of the two hormones. 7, 8 The aim of our present study was to examine the impact of prediabetic insulin resistance on plasma leptin levels, cardiac mechanical function and leptin-mediated cardiac contractile response. We took advantage of a recently developed high-sucrose diet-induced prediabetic model characterized by whole-body insulin resistance that mimics early stages of noninsulin-dependent diabetes, with only minor metabolic abnormalities such as elevated insulin and plasma triglycerides. 9, 10 Cardiac contractile properties and leptin-induced cardiac contractile response were examined in single ventricular myocytes obtained from both sucrosefed prediabetic insulin-resistant and the starch-fed control rats.
Materials and methods

Experimental animals and leptin assay
The experimental procedures were approved by the animal investigation committee of the University of North Dakota School of Medicine and Health Sciences (Grand Forks, ND, USA). In brief, adult male Sprague-Dawley rats weighing B200 g were randomly divided into two groups and fed either a cornstarch (providing 68% of total energy) or sucrose (providing 68% of total energy) diet formulated by Research Diets Incorporation (New Brunswick, NJ, USA) for 10 weeks. Plasma was collected upon killing and the supernatant was removed and stored at À41C. A leptin radioimmunoassay kit (Linco Research, St Louis, MO, USA) was used to determine the amount of leptin present in the plasma.
Glucose tolerance test
The glucose tolerance test was performed as described. 10 After the 10-week feeding period, both starch and sucrose rats were fasted for 12 h and then given an intraperitoneal (i.p.) injection of glucose (2 g/kg body weight). Blood samples were drawn from the tail 15 min and immediately before the glucose challenge, as well as 15, 60 and 120 min thereafter. Serum glucose levels were determined using an Accu-Chek III glucose analyzer (Accu-ChekII, model 792, Boehringer Mannheim Diagnostics, Indianapolis, IN, USA).
Isolation of ventricular myocytes
Ventricular myocytes were isolated as described. 10 In brief, animals were killed and hearts were removed and perfused (at 371C) with oxygenated (5% CO 2 Cell shortening/relengthening measurements Mechanical properties of ventricular myocytes were assessed using a video-based edge-detection system (IonOptix, Milton, MA, USA) as described. 10 In brief, coverslips with cells attached were placed in a chamber mounted on the stage of an inverted microscope (Olympus IX-70) and superfused (B2 ml/min at 251C) with a buffer containing (in mM) NaCl 131, KCl 4, CaCl 2 1, MgCl 2 1, glucose 10, HEPES 10, at pH 7.4. The cells were field stimulated at a frequency of 0.5 Hz, 3 ms in duration. A video-based edge detector was used to capture and convert changes in cell length during shortening and relengthening into an analog voltage signal. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS), time-to-PS (TPS) and time-to-90% relengthening (TR 90 ), maximal velocities of shortening (+dL/dt) and relengthening (ÀdL/dt).
Intracellular Ca 2+ transient measurement
For these experiments, myocytes were loaded with fura-2-AM (0.5 mM) for 10 min at 251C. Fluorescence measurements were recorded with a dual-excitation single-emission fluorescence photomultiplier system (IonOptix). Myocytes were placed on an inverted microscope and imaged through an Olympus Fluor Â 40 oil objective. Myocytes were exposed to light emitted by a 75 W halogen lamp through either a 360 or 380 nm filter while being stimulated to contract at 0.5 Hz. Fluorescence emissions were detected between 480 and 520 nm by a photomultiplier tube after initial illumination at 360 nm for 0.5 s and then at 380 nm for the duration of the recording protocol. The 360 nm excitation scan was repeated at the end of the protocol and qualitative changes in 
Experimental protocols
Myocytes (either fura-2 loaded or nonloaded) were first allowed to contract at a stimulation frequency of 0.5 Hz for 10 min to ensure steady state (myocytes with rundown 410% were not studied further) before superfusing with leptin (1-1000 nM, Sigma Chemical, St Louis, MO, USA) for 10 min. Cells were then washed with normal contractile buffer for 5 min. In a cohort of studies, the nitric oxide synthase (NOS) inhibitor No-nitro-L-arginine methyl ester (L-NAME, 100 mM, Sigma), the JAK/STAT inhibitor AG-490 (20 mM, Sigma) or the MAP kinase inhibitor SB203580 (20 mM, Sigma) was preincubated with the myocytes for 10 min prior to leptin addition. In some studies, extracellular Ca 2+ was elevated from the normal levels of 1.0 to 2.7 mM to assess the effect on leptin-induced contractile response.
Data analysis
For each experimental series, data are presented as mean7 s.e.m. Statistical significance (Po0.05) for each variable was estimated by two-way analysis of variance (ANOVA) or t-test, where appropriate.
Results
Experimental animals and plasma leptin level
The sucrose-fed rats exhibited significantly elevated plasma leptin levels compared to the starch-fed counterparts (Table 1) . There is no difference in body weight, heart weight or organ-to-body weight ratio of heart, livers and kidney between the starch-and sucrose-fed rats. Following the acute intraperitoneal glucose challenge, the plasma glucose levels in the starch-fed rats started to decline after peaking at 15 min, and nearly returned to the baseline value after 120 min. However, the post-challenge glucose level remained at much higher levels between 15 and 120 min in the sucrose-fed rats (Figure 1 ), indicating impaired glucose clearance, an indicative of glucose intolerance and insulin resistance, in the sucrose-fed rats. There was no difference in basal fasting glucose levels between the two groups, excluding the presence of diabetes.
Baseline mechanical and fluorescent properties of myocytes from starch-and sucrose-fed rats Insulin resistance is known to increase the propensity of cardiac hypertrophy although our results did not show any difference in the resting cell length (CL) between the starch and sucrose groups. The peak shortening amplitude (PS) and maximal velocities of shortening and relengthening (7dL/dt) were both significantly depressed in myocytes from the sucrose group compared to those from the starch group. Sucrose myocytes displayed a significantly shortened TPS and prolonged TR 90 compared to those from the starch group ( Figure 2 ). The intracellular fura-2 fluorescent recording provided supportive observations to the mechanical findings. The electrically stimulated fura-2 fluorescent rise (DFFI) was depressed and intracellular Ca 2+ clearing rate (t) was slowed, consistent with reduced PS and prolonged TR 90 in sucrose-fed group. The resting intracellular Ca 2+ levels (baseline FFI) were comparable in myocytes between the two groups ( Figure 3 ). In addition, neither starch-nor sucrose-fed rat myocytes responded to externally administered insulin at 1 mM (percent change from baseline: À2.2574.76 and 1.3078.03% in starch and sucrose groups, respectively, n ¼ 12 cells per group). The inability of insulin to affect myocyte shortening was consistent with our earlier observation.
11 Acute exposure (up to 15 min) of leptin did not affect the resting CL over the concentration range tested (1-1000 nM).
Representative traces depicting the effect of leptin (500 nM) on myocyte shortening are shown in Figure 4 . At the end of a 10-min exposure to this concentration of leptin, myocyte shortening was decreased by B16 and B21% in myocytes from starch and sucrose groups, respectively. Figure 4c shows that leptin induced a comparable concentration-dependent depression of myocyte shortening in myocytes from starch and sucrose groups with maximal inhibitions of 22.3% and 22.9%, respectively. The threshold of response was between 10 and 100 nM. The depressive effect of leptin on PS was maximal within 8 min and was reversible upon washout. ] i in response to electrical stimuli in the presence of leptin (1-1000 nM) was examined. Figure 4d depicts that leptin elicited a concentration-dependent inhibition of DFFI, with maximal inhibitions of 19.6 and 14.3% in starch and sucrose myocytes, respectively. The threshold of DFFI response was between 100 and 500 nM. The inhibitory response of DFFI suggests that a decrease in intracellular free Ca 2+ recruitment is likely to be responsible for leptin-induced depressive action on myocyte shortening. Neither baseline FFI (resting Ca 2+ level) nor t was affected by leptin in either rat group (data not shown).
Effect of leptin on PS in the presence of L-NAME and elevated extracellular Ca
2+
Leptin has been shown to stimulate NOS and enhance NO production, an important regulator in the cardiovascular system. 12, 4 Constitutive NOS (cNOS) and inducible NOS (iNOS) are both present in ventricular myocytes. 13, 14 To examine if NO is involved in the action of leptin in starch and sucrose myocytes, the effect of leptin on PS was reexamined in the presence of the NOS inhibitor L-NAME (100 mM). L-NAME alone had no effect on PS over 30 min (data not shown). As shown in Figure 5a , the leptin-induced decrease in PS was completely abolished by L-NAME in myocytes from both starch and sucrose groups. These data suggest that leptin may exert its inhibition on PS, at least in part, through NO production. More interestingly, the leptininduced depression of PS was reverted to a significantly positive response in the presence of L-NAME in the starch group, indicating intrinsic positive inotropicity by the hormone. To evaluate if leptin-induced cardiac contractile depression was due to reduced extracellular Ca 2+ influx, extracellular Ca 2+ level was increased from the normal 1.0 to 2.7 mM before the leptin response on PS was re-examined. Figure 5b shows that the leptin-induced cardiac depressive effect is ablated by increased extracellular Ca
, indicating that the leptin-induced depression of cardiac contraction may be related to reduced intracellular Ca 2+ recruitment in both starch-and sucrose-fed rat hearts.
Effect of leptin on PS in the presence of AG-490 and SB203580
Both JAK/STAT and MAP kinase pathways have been shown to be involved in the cardiac contractile response of leptin. 15, 16, 5 To examine if JAK/STAT and MAP kinase were involved in the leptin-induced cardiac contractile response under the current experimental setting, the effect of leptin on PS was re-examined by preincubating the cells with the JAK2 inhibitor AG-490 (20 mM) or the MAP kinase inhibitor SB203580 (20 mM) for 15 min. Neither inhibitor alone had any effect on PS. 5 Interestingly, both inhibitors not only Leptin resistance and insulin resistance KK Hintz et al abolished the leptin-induced decrease in PS but also unmasked a positive PS response in myocytes from both groups, suggesting that leptin may exert its inhibition on PS through JAK2 and/or MAP kinase pathways and also possess an intrinsic positive action on cardiac contraction ( Figure 6 ).
Discussion
This is the first study to examine the effect of insulin resistance on plasma leptin levels and leptin-induced cardiac contractile response in cardiac myocytes. The major findings of our study are that prediabetic insulin resistance elicits hyperleptinemia and cardiac contractile dysfunction without cardiac resistance to leptin. Leptin induced comparable concentration-dependent depressions of myocyte shortening and intracellular Ca 2+ transients between starch-fed and sucrose-fed rat myocytes. Leptin-induced inhibition in cardiac contraction was abolished by the NOS inhibitor L-NAME, selective inhibitors of JAK/STAT and MAP kinase, or elevation of extracellular Ca
2+
. Furthermore, leptin seems to possess an intrinsic positive inotropic action independent of the signaling mechanisms tested in our study. These data suggest that cardiac leptin resistance may not be overtly present prior to insulin resistance or cardiac contractile dysfunction due to prediabetic insulin resistance.
Insulin resistance and hyperinsulinemia are often associated with obesity, hypertension, dyslipidemia and glucose intolerance. Insulin resistance and hyperinsulinemia are considered to impair cardiovascular function through increased blood pressure via sympathetic activation, reninangiotensin system stimulation and direct alteration of cardiac myocyte function. 10, 17 Alleviating insulin resistance by lifestyle modification including diet, weight loss and physical exercise has been shown to improve cardiac function and reduce blood pressure. Angiotensin-converting enzyme inhibitors, vasodilatory b-blockers and L-type Ca 2+ channel blockers have been reported to improve insulin sensitivity and elicit a beneficial effect on insulin resistance. 18 Insulin has been shown to be an important regulator of leptin secretion. 19 However, it has been demonstrated that reduction of insulin sensitivity or insulin-mediated glucose uptake rather than insulin per se diminishes the stimulatory effect of insulin on leptin secretion and regulates circulating leptin levels. 20 Circulating leptin appears to be one of the best biological markers of obesity. Leptin is increased under obesity, and (from 1.0 to 2.7 mM) on leptin-induced response in PS in myocytes from starch-and sucrose-fed rat hearts. mean7s.e.m., sample size is given in parentheses. *Po0.05 vs baseline value, #Po0.05 vs respective starch or sucrose groups without L-NAME or elevated Ca 2+ , $Po0.05 vs starch+L-NAME group. Leptin resistance and insulin resistance KK Hintz et al hyperleptinemia is closely associated with several metabolic risk factors related to insulin resistance in diabetes or obesity. 21, 22 However, there is a considerable variability between leptin levels and body mass index, suggesting that genetic and environmental factors may regulate leptin levels. Results from our current study suggested that leptin levels are associated with insulin resistance or impaired insulin secretion. This is supported by the observation that leptin level is correlated with insulin levels independent of obesity and body fat distribution after adjustment for age, gender and ethnicity. 6, 8, 23 Although it was suggested that individuals with increased insulin levels may likely be relatively leptin resistant, 7 our current study failed to find cardiac leptin resistance as an immediate consequence of insulin resistance. In this study, the leptin-induced cardiac contractile depression was abolished by the NOS inhibitor L-NAME in myocytes from both starch-and sucrose-fed rats. This is consistent with our earlier observation that leptin depresses cardiac contraction via an NO-mediated mechanism. 4, 5 NO is considered as a likely 'universal mediator' in the leptinassociated cardiovascular response. 12, 24 However, myocytes from the starch group displayed a significantly positive response in PS in the presence of L-NAME compared to those from the sucrose group. This discrepancy may be due to possible NO-unrelated intrinsic properties of leptin between the starch and sucrose myocytes. In addition, myocyte contractility in the presence of L-NAME is higher in the starch group than in the sucrose group, suggesting that myocyte contraction due to intrinsic properties of leptin may be attenuated by the insulin-resistant prediabetic state. The potential intrinsic positive cardiac contractile response of leptin was further supported by the significant positive response of leptin in the presence of the JAK2 or MAK kinase inhibitors. The comparable cardiac contractile response of leptin in the presence of AG-490 or SB203580 between the two groups indicated that insulin resistance is unlikely to affect the leptin-mediated signaling in JAK/STAT and MAP kinase in the hearts. The observation that elevated extracellular Ca 2+ concentration ablates leptin-induced cardiac depression lends support to the fact that the leptin-induced cardiac response through JAK/STAT, MAP kinase and/or NO may be due to a final route of reduced intracellular Ca 2+ accumulation during excitation. Leptin has been considered a key factor in the regulation of cardiovascular function. Leptin is known to induce vasodilation, depress cardiac contractile function, facilitate glucose metabolism, increase insulin sensitivity and improve the lipid profile. 5, 25 The vasodilatory effect of leptin may work in concert with its cardiac depressive property to alleviate the increased after-and preload of the hearts, which is often seen in obesity under a sympathetic overdrive. [1] [2] [3] 6 Elevated plasma leptin level, or hyperleptinemia, may lead to leptin resistance and pathological conditions such as hypertension and obesity. 2, 25 Increased food intake has been shown to rapidly induce leptin resistance and thus contribute to the obesity-associated cardiovascular dysfunctions. 23 These observations may have prompted to the speculations that endogenously produced leptin acts as a physiological regulator of cardiovascular function, whereas hyperleptinemia or leptin resistance serves as pathophysiological indicator of cardiovascular diseases.
In conclusion, hyperleptinemia and impaired leptin function have been demonstrated in insulin-resistant states such as hypertension and obesity. 21, 22, 26 Our present study indicated that insulin resistance contributes to hyperleptinemia associated with cardiac contractile dysfunctions; however, it may not necessarily lead to cardiac leptin resistance. Although our study sheds some light on the interaction of insulin resistance and hyperleptinemia on cardiovascular function under obesity, the pathogenesis of cardiac contractile dysfunction under obesity still deserves further study. It is important to delineate the action of the leptin receptor under obesity and insulin resistance, and understand its response to increased levels of leptin. It is also imperative that we understand the direct role of long-lasting insulin resistance in the cardiac dynamics in response to leptin.
